The global biobanks market size was estimated at USD 81.29 billion in 2024 and is expected to grow at a CAGR of 7.85% from 2025 to 2030. High investments in the R&D of advanced therapies, such as regenerative medicine, personalized medicine, and cancer genomic studies, are some of the driving factors.
Moreover, the onset of COVID-19 has put biobanks at the forefront of the pandemic control measures, resulting in the organic revenue growth of the market. The COVID-19 outbreak had a major influence on the biobanks industry. Biobanking is important for the diagnosis & production of medicines for a variety of disorders. International initiatives to produce vaccines and other medicines to prevent the spread of the virus have been urgently needed.
The collection, processing, and analysis of patient samples are at the frontline of the COVID-19 crisis. For example, the Health Minister announced EUR 2 million in financing for the National Irish COVID-19 Biobank (NICB) in a July 2021 update from the Government of Ireland. The NICB has become a critical part of Ireland’s COVID-19 pandemic response. According to a February 2021 release, the Sample Collection Database was designed by the SciLifeLab Data Centre in partnership with Biobank Sweden and the research area ‘Biobanks for COVID-19’ of the SciLifeLab & KAW National COVID-19 research program. Furthermore, Tulane University announced a new COVID-19 biobank containing blood & cell samples from survivors in July 2021 to aid researchers in determining why some people heal rapidly while others have long-term effects. As a result, such activities show that the outbreak of the pandemic boosted the demand for biobank services, benefiting the global economy.
The increasing popularity of precision/personalized medicine and genetic testing has been a key driver of the market. Biobanks have been playing a significant role in biomedical research. Over the past few decades, there have been several advances in platforms and tools used in genetic studies. This has led to an increase in demand for biospecimens from clinical labs to develop assays for genetic testing. Collaborations between private and public institutions in biobanking have played a crucial role in market progression.
Digitalization, precision medicine, and virtualization are rapidly changing the biobanking industry through the development of novel methods and concepts of collaborations initiated by public and private organizations. Companies across all fields are partnering with biobanks, which accelerates the market revenue. For instance, in October 2023, UK Biobank partnered with several philanthropists. Through this partnership, UK Biobank will access USD 34.5 million in funding.
An exponential increase in the number of global cases has rendered the significance of biobanks in containing the spread of the virus. High-quality COVID-19 specimens are required and helpful for both research and diagnostic purposes, and biobanks are considered vital repositories for these samples. Thus, biobanks are gaining ground to support clinical research and drug discovery processes to combat this global disaster.
Furthermore, developing countries from the Middle East region are investing in biobanks to advance the medical research domain in the region. For instance, in September 2023, the Crown Prince of Abu Dhabi announced the launch of a biobank to support the requirement of personalized medicine through advanced treatments that utilize human tissues and stem cells in medical research. This research will help treat over 80 diseases and immune system issues. Moreover, it strengthens the position of the UAE in the global biobank market.
Biobanks play a critical role in advancing biomedical research by systematically collecting, storing, and managing biological specimens and associated data. These repositories support a wide range of applications, including drug discovery, genomics, personalized medicine, and public health studies. Below is a list of some of the largest and most influential biobanks operating globally, recognized for their scale, diversity of samples, and research impact.
Name |
Size |
Sample Type |
Biobank Graz |
20 million |
Serum, EDTA-plasma, buffy coat, urine, whole blood, Na-citrate plasma, fresh frozen tissue, FFPE tissue, PAXgene blood, cerebrospinal fluid, stool, throat swabs, placenta, umbilical cord blood, mononuclear cells. |
Shanghai Zhangjiang Biobank |
10 million |
It is reported that the biobank is projected to reach a storage capacity of 10 million human-derived samples, such as human tissue, cells, blood, and intestinal microflora. |
“All of Us” Biobank |
1 million |
Blood, urine, saliva, physical measurements, electronic health records, wearable device data. |
The International Agency for Research on Cancer (IARC) Biobank (IBB) |
562,000 |
Most of the samples are body fluids, including plasma, serum, urine, and extracted DNA samples |
China Kadoorie Biobank |
510,000 |
Blood (plasma, buffy coat), urine, saliva, fecal samples. |
UK Biobank |
500,000 |
Blood, urine, saliva, physical measurements, imaging data, genetic data, and health records. |
FINNGEN biobanks |
500,000 |
Blood samples, DNA, and health registry data. |
Canadian Partnership for Tomorrow’s Health |
330,000 |
Blood, urine, physical measurements, lifestyle and health questionnaires. |
Estonian Biobank |
200,000 |
DNA, blood, phenotype data, microbiome samples, RNA, and metabolomics data. |
EuroBioBank network |
150,000 |
DNA, RNA, plasma, serum, muscle tissue, fibroblasts, cell lines, and other rare disease biospecimens |
Source:Biobanking.com
The biobanks market has witnessed significant innovation, from traditional sample storage to incorporating advanced data management, analytics tools, and automation. Integration of omics technologies, such as genomics, and increased collaboration globally have further enhanced research capabilities. These developments accelerate biomedical research and contribute to the evolution of personalized medicine.
The biobanks market is also characterized by a high level of mergers and acquisitions (M&A) activity by the leading players. This is due to several factors, including the desire to gain access to new biobank technologies and talent, the need to consolidate in a rapidly growing market, and its usage in research and development.
The market is also subject to increasing regulatory scrutiny. These regulations dictate the responsible collection, storage, and use of biological samples, emphasizing informed consent, privacy protection, and data security. Compliance is crucial for ensuring the reliability of stored samples, facilitating international collaboration, and addressing emerging ethical considerations related to advancements in technologies such as genomics and data analytics.
Product expansion in the biobanks market involves strategic initiatives to introduce new services and offerings. The key players focus on diversifying sample collections, implementing advanced data management systems, providing specialized services, creating collaborative platforms, integrating omics technologies, adopting automation, and establishing global partnerships.
In the biobanks industry, regional expansion involves biobanking entities strategically broadening their activities beyond current geographic boundaries. Hence, key players undertake several business initiatives, such as geographical expansion, partnerships, and collaboration, to gain a regional customer base.
The services segment dominated the market and accounted for the largest revenue share in 2024 and is anticipated to grow at the fastest CAGR during the forecast period. Governments and research organizations are investing heavily in large-scale genomics and biomarker studies, creating sustained demand for high-quality biospecimen collection, processing, and storage. Additionally, advancements in biobanking technologies, such as automated storage systems, digital sample tracking, and cloud-based data integration, are enhancing the efficiency and scalability of biobank operations. Regulatory support and collaborations between academia, industry, and healthcare institutions further accelerate the adoption of biobanking services.
The product segment is anticipated to grow at a significant CAGR during the forecast period. The growth of this segment is primarily driven by the growing need for advanced storage and preservation equipment to support the rising volume and diversity of biological samples used in research and clinical applications. In February 2023, UK Biobank announced that it made a public dataset from 45,000 Magnetic Resonance Imaging (MRI) scans.
Based on biospecimen type, the global biobanks market has been categorized into human tissues, organs, stem cells, and other biospecimen. The human tissues segment captured the largest revenue share of 36.74% in 2024, owing to a large number of biobanks with facilities to store tissues, easy availability of tissue samples, and availability of advanced technology for storage and retrieval of banked tissues. Growing investment in disease-specific R&D is anticipated to foster the demand for diseased tissue samples, such as lymphoma, myeloma, ovarian leukemia, brain, prostate, colorectal carcinoma, breast, and lung tissues for oncology studies.
In the effort to advance the research on COVID-19 and improve its diagnosis and treatment, the stem cells segment is expected to witness the fastest growth during the forecast period. The number of established stem cell biobanks has been increasing rapidly worldwide. Promising applications of stem cells in regenerative medicine, cell therapy, developmental biology, toxicology, and drug development can be attributed to the rapid increase in the number of stem cell banks. Preservation of cellular characteristics, preventing deterioration & contamination, use in basic & translation research, and potential and current use in clinical applications are factors that significantly contributed to the adoption of stem cell banking.
Based on biobanks type, the global market is bifurcated into physical/real biobanks and virtual biobanks. The physical/real biobanks segment dominated the market in 2024 and accounted for the largest revenue share of 75.24%. These biobanks have a well-established network, thereby holding a high revenue share. Rapid progress in the fields of bioinformatics analysis and precision medicine can be attributed to this change in the operating strategy of the biobanks. A large collection of tissue samples from pathological labs, clinical trials, and research projects over the years contributes to the largest share of tissue banks in 2024.
The virtual biobanks segment is expected to witness the fastest CAGR over the forecast period. Virtual biobanks have emerged to address the problems related to the accessibility of biospecimen. Tissue Solutions (Scotland) and Human Focused Testing (Little port) are examples of organizations whose core operating activity involves procurement and distribution of samples as per requirement. The potential to fulfill the need for biospecimens and the ability to trace and obtain rare samples improves with virtual biobanking. Also, easy accessibility associated with virtual biobanks contributes to the lucrative growth of the segment.
Based on application, the biobanks industry is categorized into therapeutics, drug discovery & clinical research, clinical diagnostics, and other applications. In 2024, the therapeutics application segment dominated the market with the largest revenue share of 37.63%. This can be attributed to the ever-increasing demand for advanced therapies for treatment of chronic diseases. The exponential increase in the number of COVID-19 cases across the globe has resulted in an increasing need for development of novel viral therapeutics. Various studies are being conducted to accelerate research in this field.
On the other hand, the clinical diagnostics segment is anticipated to witness a significant growth over the forecast period. Comparison of biospecimen obtained from healthy and diseased individuals advances the clinical diagnosis process, especially for cancer. It helps investigate the treatment response of the patient and identify a new tumor in a patient with a history of cancer.
North America accounted for the second largest revenue share of the biobanks industry in 2024, owing to the advanced healthcare infrastructure, strong government and private sector funding for genomics and personalized medicine, and a well-established regulatory framework supporting biobanking practices. The presence of large-scale initiatives like the NIH-funded “All of Us” research program and extensive academic and commercial research in genomics fuel demand for biobanking services and products. High awareness and adoption of digital and automated storage solutions further accelerate market growth in the region.
In the U.S., biobank industry’s growth is propelled by major government-led initiatives in precision medicine, increasing investments in cancer and rare disease research, and the presence of prominent research institutions and pharmaceutical companies. Programs like the National Cancer Institute’s biorepositories and increased focus on interoperability of health data are pushing for standardized and scalable biobanking solutions. The country also benefits from a mature digital health ecosystem that supports efficient sample and data management.
Europe biobanks industry accounted for the largest revenue share of 39.37% in 2024, owing to the continuous investment in the collection, establishment, and processing of large-scale datasets. Furthermore, countries like the UK, Germany, and France are contributing to the regional market growth by investing in biobank solutions. For instance, in June 2023, The Medicines and Healthcare products Regulatory Agency (MHRA) collaborated with Genomics England to launch its genetic biobank.
The UK biobanks market growth is significantly driven by national-scale programs such as the UK Biobank project, which supports broad research initiatives in public health, genomics, and epidemiology. Strong academic-industry collaboration, government support, and integration of biobanking into NHS-backed health research projects contribute to the robust demand for biobanking infrastructure and data analytics tools. Additionally, policy support around open data sharing fosters innovation and multi-institutional collaboration.
The biobanks market in Germany is influenced by initiatives like the German Biobank Node (GBN) and its integration into the Network of University Medicine (NUM), aimed at centralizing and digitizing biobanking resources. Federal funding through agencies like BMBF supports the development of standardization, quality control, and cross-institutional interoperability, while strong pharmaceutical and diagnostics sectors drive sample demand. Advanced hospital networks and academic research institutions also support market expansion.
The Asia Pacific biobanks industry is expected to witness the fastest CAGR over the forecast period. The growth can be attributed to the investment of developing economies like India, China, and Japan. These countries are actively engaged in developing the biobank market by undertaking several business initiatives to strengthen their market position. For instance, in November 2023, AIG Hospital launched its first biobank in India’s southern region. The biobank will collect over one lakh tissue and blood samples for the upcoming decade.
China biobanks market is rapidly expanding, fueled by national efforts to become a global leader in biomedical research, large-scale population genomics projects, and increasing health data digitization. Government-backed initiatives like the China Kadoorie Biobank and rising investment in biotechnology create significant demand for storage systems, sample prep, and high-throughput sequencing tools. Local manufacturing growth and foreign collaborations further stimulate the product and services landscape.
The biobanks market in Japan benefits from a strong emphasis on aging-related and personalized medicine research. Government-funded efforts such as BioBank Japan support large-scale health data collection, particularly for chronic disease research. Technological innovation, combined with Japan’s high standard of healthcare and research integrity, fosters strong demand for integrated biobanking solutions. Additionally, collaborations with global biopharma companies push demand for standardized and automated systems.
The Middle East & Africa region shows growing interest in biobanking due to increasing investments in healthcare infrastructure, precision medicine, and population health research. Countries like the UAE and Qatar are developing national biobank programs, while Africa is seeing rising participation in infectious disease and genomics studies. However, challenges like limited standardization and funding disparities remain, although international collaborations are helping to close gaps and drive adoption.
Saudi Arabia’s biobanks market is expanding as part of its Vision 2030 strategy, which includes a strong focus on healthcare digitization and genomics. The launch of national initiatives such as the Saudi Human Genome Program and investments in biotech parks and research universities are fueling the need for advanced biobanking systems. Strong government backing and a push for personalized healthcare solutions support both infrastructure and product market growth.
The biobanks market in Kuwait is expected to develop in tandem with public health and precision medicine initiatives, with support from the Ministry of Health and regional research collaborations. Focused efforts on chronic disease research, especially diabetes and cardiovascular conditions, are driving demand for sample collection and storage infrastructure. However, the market is still at an early stage and is likely to benefit from partnerships with global biobank technology providers.
The biobanking market is supported by key players such as Thermo Fisher Scientific Inc., Merck KGaA, Qiagen, Stemcell Technologies, and PromoCell GmbH, each offering specialized products and services. Thermo Fisher dominates with a broad portfolio including cryogenic storage, automated sample handling, and data management systems, making it a comprehensive solutions provider with a global footprint. Merck KGaA focuses on cell culture media, cryopreservation reagents, and biobank-compatible consumables, leveraging its strong European presence.
Qiagen is known for its sample preparation kits and automation systems like QIAsymphony and QIAcube, particularly suited for genomic and molecular biobanking. Stemcell Technologies supports regenerative medicine and stem cell biobanking with advanced cell culture tools and reagents, particularly in North America and Europe. PromoCell GmbH, while more niche, contributes through its high-quality human primary cells and cryopreserved samples used in research biobanks across Europe. Together, these players represent the technological and regional diversity driving innovation and adoption in the biobanking product and service landscape.
Some of the key players operating in the market are adopting various organic & inorganic strategies, such as collaborations with biobanking service providers and technological innovation to advance their product offerings in the biobanking industry.
The following are the leading companies in the biobanks market. These companies collectively hold the largest market share and dictate industry trends.
In July 2025, the German Biobank Node (GBN) will become part of the Network of University Medicine (NUM). This integration aligns with the recent approval of NUM’s new funding phase (NUM 3.0) by the Federal Ministry of Education and Research (BMBF) last week.
In May 2024, EIT Health introduced a new Biobanks and Health Data Portal designed to enhance collaboration and promote the broader use of biobanks.
In December 2023, Charles River Laboratories International, Inc. announced an agreement with CELLphenomics. The CELLphenomics biobank has over 500 in vitro models from around 20 tumor entities. It offers one of the largest complex in vitro models of rare and ultra-rare tumors like thymomas or sarcomas.
In October 2023, AstraZeneca research announced unique relationships between rare changes in plasma proteins and genes that could enhance drug discovery with data from more than 50,000 UK Biobank participants.
In July 2023, Tecan announced the launch of Phase Separator. It has several applications in biobanking and liquid biopsy and is expected to benefit proteomics, genomics, and across numerous disease areas, from neurodegenerative and oncology diseases to metabolic disorders.
Report Attribute |
Details |
Market size value in 2025 |
USD 86.82 billion |
Revenue forecast in 2030 |
USD 126.69 billion |
Growth rate |
CAGR of 7.85% from 2025 to 2030 |
Actual data |
2018 - 2024 |
Forecast period |
2025 - 2030 |
Quantitative units |
Revenue in USD million/billion, and CAGR from 2025 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, biospecimen type, biobanks type, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Thermo Fisher Scientific Inc.; Merck KGaA; Qiagen; Hamilton Company; Tecan Trading AG; Danaher Corporation; Becton, Dickinson, and Company (BD); Biocision, LLC.; Taylor-Wharton; Charles River Laboratories; Lonza; Stemcell Technologies; Biovault Family; Promocell GmbH; Precision Cellular Storage Ltd. (Virgin Health Bank) |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global biobanks market report based on product & service, biospecimen type, biobanks type, application, and region:
Product & Services Outlook (Revenue, USD Million, 2018 - 2030)
Product
Biobanking Equipment
Temperature Control Systems
Freezers & Refrigerators
Cryogenic Storage Systems
Thawing Equipment
Incubators & Centrifuges
Alarms & Monitoring Systems
Accessories & Other Equipment
Biobanking Consumables
Laboratory Information Management Systems
Services
Biobanking & Repository
Lab processing
Qualification/ Validation
Cold Chain Logistics
Other Services
Biospecimen Type Outlook (Revenue, USD Million, 2018 - 2030)
Human Tissues
Human Organs
Stem Cells
Adult Stem Cells
Embryonic Stem Cells
IPS Cells
Other Stem Cells
Other Biospecimens
Biobanks Type Outlook (Revenue, USD Million, 2018 - 2030)
Physical/Real Biobanks
Tissue Biobanks
Population Based Biobanks
Genetic (DNA/RNA)
Disease Based Biobanks
Virtual Biobanks
Application Type Outlook (Revenue, USD Million, 2018 - 2030)
Therapeutics
Drug Discovery & Clinical Research
Clinical Diagnostics
Other Applications
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Italy
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
b. The global biobank market size was estimated at USD 81.29 billion in 2024 and is expected to reach USD 86.82 billion in 2025.
b. The global biobank market is expected to grow at a compound annual growth rate of 7.85% from 2025 to 2030 to reach USD 126.69 billion by 2030.
b. On the basis of product & services, the services segment dominated the market and accounted for the largest revenue share in 2024 and is anticipated to grow at the fastest CAGR during the forecast period. Governments and research organizations are investing heavily in large-scale genomics and biomarker studies, creating sustained demand for high-quality biospecimen collection, processing, and storage. Additionally, advancements in biobanking technologies—such as automated storage systems, digital sample tracking, and cloud-based data integration—are enhancing the efficiency and scalability of biobank operations.
b. Some key players operating in the biobank market include Thermo Fisher Scientific Inc.; Merck KGaA; QIAGEN; Hamilton Company; Tecan Trading AG; Danaher Corporation; Becton, Dickinson and Company (BD); BioCision, LLC; Taylor-Wharton; Charles River Laboratories; Lonza; STEMCELL Technologies; Biovault Family; PromoCell GmbH; Precision Cellular Storage Ltd. (Virgin Health Bank)
b. Key factors that are driving the biobank market growth are the increasing popularity of fertility preservation services, investment in facility expansion for biobanking, and growing collaborations between biobanks and end-users.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product & Services
1.2.2. Biospecimen Type
1.2.3. Biobanks Type
1.2.4. Application
1.3. Research Methodology
1.4. Information Procurement
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Biobanks Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Continuous increase in COVID-19 cases along with capacity expansion
3.2.1.2. Increased focus on precision medicine and genetic testing
3.2.1.3. Changes in biobanking operations
3.2.1.4. Increase in the number of clinical trials globally
3.2.1.5. Growing industry and research collaborations
3.2.1.6. Technology advancement and automation
3.2.2. Market restraint analysis
3.2.2.1. Disruptions in supply chain management due to COVID-19
3.2.2.2. Challenges in sharing biobanking data & limited access to biospecimens
3.2.2.3. Sustainability challenges for biobanks
3.2.2.4. Other challenges in biobanking specimens for research
3.3. Biobanks Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. Biobanks Market: Product & Services Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Product & Services Market Share, 2024 & 2030
4.3. Product
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Biobank Equipment
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Temperature Control Systems
4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2.2. Freezers & Refrigerators
4.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2.3. Cryogenic Storage Systems
4.4.1.2.4. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2.5. Thawing Equipment
4.4.1.2.6. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Incubators & Centrifuges
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Alarms & Monitoring Systems
4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Accessories & Other Equipment
4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Biobanking Consumables
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Laboratory Information Management Systems
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Services
4.6. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.6.1. Biobanking & repository
4.6.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.2. Lab processing
4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.3. Qualification/ Validation
4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.4. Cold Chain Logistics
4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.5. Other Services
4.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Biobanks Market: Biospecimen Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Biospecimen Type Market Share, 2024 & 2030
5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.3.1. Human Tissues
5.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
5.3.2. Human Organs
5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.3.3. Stem Cells
5.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.3.3.2. Adult Stem Cells
5.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.3.3.3. Embryonic Stem Cells
5.3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.3.3.4. IPS Cells
5.3.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.3.3.5. Other Stem Cells
5.3.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.3.4. Other biospecimens
5.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Biobanks Market: Biobanks Type Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Biobanks Type Market Share, 2024 & 2030
6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.3.1. Physical/Real biobanks
6.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.3.1.2. Tissue Biobanks
6.3.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.1.3. Population based biobanks
6.3.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.1.4. Genetic (DNA/RNA)
6.3.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.1.5. Disease based biobanks
6.3.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Virtual biobanks
6.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Biobanks Market: Application Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Application Market Share, 2024 & 2030
7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.3.1. Therapeutics
7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Drug discovery & clinical research
7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Clinical Diagnostics
7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.4. Other Applications
7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Biobanks Market: Regional Estimates & Trend Analysis
8.1. Regional Market Dashboard
8.2. Regional Market Share Analysis, 2024 & 2030
8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
8.4.1. U.S.
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.4.2. Canada
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.4.3. Mexico
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Europe
8.5.1. UK
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.5.2. Germany
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.5.3. France
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.5.4. Italy
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.5.5. Spain
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.5.6. Norway
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.5.7. Sweden
8.5.7.1. Key country dynamics
8.5.7.2. Regulatory framework/ reimbursement structure
8.5.7.3. Competitive scenario
8.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.5.8. Denmark
8.5.8.1. Key country dynamics
8.5.8.2. Regulatory framework/ reimbursement structure
8.5.8.3. Competitive scenario
8.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Asia Pacific
8.6.1. Japan
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.6.2. China
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.6.3. India
8.6.3.1. Key country dynamics
8.6.3.2. Regulatory framework/ reimbursement structure
8.6.3.3. Competitive scenario
8.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.6.4. Australia
8.6.4.1. Key country dynamics
8.6.4.2. Regulatory framework/ reimbursement structure
8.6.4.3. Competitive scenario
8.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.6.5. South Korea
8.6.5.1. Key country dynamics
8.6.5.2. Regulatory framework/ reimbursement structure
8.6.5.3. Competitive scenario
8.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.6.6. Thailand
8.6.6.1. Key country dynamics
8.6.6.2. Regulatory framework/ reimbursement structure
8.6.6.3. Competitive scenario
8.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.7. Latin America
8.7.1. Brazil
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.7.2. Argentina
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.8. MEA
8.8.1. South Africa
8.8.1.1. Key country dynamics
8.8.1.2. Regulatory framework/ reimbursement structure
8.8.1.3. Competitive scenario
8.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.8.2. Saudi Arabia
8.8.2.1. Key country dynamics
8.8.2.2. Regulatory framework/ reimbursement structure
8.8.2.3. Competitive scenario
8.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.8.3. UAE
8.8.3.1. Key country dynamics
8.8.3.2. Regulatory framework/ reimbursement structure
8.8.3.3. Competitive scenario
8.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.8.4. Kuwait
8.8.4.1. Key country dynamics
8.8.4.2. Regulatory framework/ reimbursement structure
8.8.4.3. Competitive scenario
8.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company/Competition Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2024
9.4. Company Profiles/Listing
9.4.1. Thermo Fisher Scientific Inc.
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Merck KGaA
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Qiagen
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. Hamilton Company
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Tecan Trading AG
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Danaher Corporation
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Becton, Dickinson, and Company (BD)
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. Biocision, LLC.
9.4.8.1. Company overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Taylor-Wharton
9.4.9.1. Company overview
9.4.9.2. Financial performance
9.4.9.3. Product benchmarking
9.4.9.4. Strategic initiatives
9.4.10. Charles River Laboratories
9.4.10.1. Company overview
9.4.10.2. Financial performance
9.4.10.3. Product benchmarking
9.4.10.4. Strategic initiatives
9.4.11. Lonza
9.4.11.1. Company overview
9.4.11.2. Financial performance
9.4.11.3. Product benchmarking
9.4.11.4. Strategic initiatives
9.4.12. Stemcell Technologies
9.4.12.1. Company overview
9.4.12.2. Financial performance
9.4.12.3. Product benchmarking
9.4.12.4. Strategic initiatives
9.4.13. Biovault Family
9.4.13.1. Company overview
9.4.13.2. Financial performance
9.4.13.3. Product benchmarking
9.4.13.4. Strategic initiatives
9.4.14. Promocell GmbH
9.4.14.1. Company overview
9.4.14.2. Financial performance
9.4.14.3. Product benchmarking
9.4.14.4. Strategic initiatives
9.4.15. Precision Cellular Storage Ltd. (Virgin Health Bank)
9.4.15.1. Company overview
9.4.15.2. Financial performance
9.4.15.3. Product benchmarking
9.4.15.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America biobanks market, by region, 2018 - 2030 (USD Million)
Table 3 North America biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 4 North America biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 5 North America biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 6 North America biobanks market, by application, 2018 - 2030 (USD Million)
Table 7 U.S. biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 8 U.S. biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 9 U.S. biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 10 U.S. biobanks market, by application, 2018 - 2030 (USD Million)
Table 11 Mexico biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 12 Mexico biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 13 Mexico biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 14 Mexico biobanks market, by application, 2018 - 2030 (USD Million)
Table 15 Canada biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 16 Canada biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 17 Canada biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 18 Canada biobanks market, by application, 2018 - 2030 (USD Million)
Table 19 Europe biobanks market, by region, 2018 - 2030 (USD Million)
Table 20 Europe biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 21 Europe biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 22 Europe biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 23 Europe biobanks market, by application, 2018 - 2030 (USD Million)
Table 24 Germany biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 25 Germany biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 26 Germany biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 27 Germany biobanks market, by application, 2018 - 2030 (USD Million)
Table 28 UK biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 29 UK biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 30 UK biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 31 UK biobanks market, by application, 2018 - 2030 (USD Million)
Table 32 France biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 33 France biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 34 France biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 35 France biobanks market, by application, 2018 - 2030 (USD Million)
Table 36 Italy biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 37 Italy biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 38 Italy biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 39 Italy biobanks market, by application, 2018 - 2030 (USD Million)
Table 40 Spain biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 41 Spain biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 42 Spain biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 43 Spain biobanks market, by application, 2018 - 2030 (USD Million)
Table 44 Denmark biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 45 Denmark biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 46 Denmark biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 47 Denmark biobanks market, by application, 2018 - 2030 (USD Million)
Table 48 Sweden biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 49 Sweden biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 50 Sweden biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 51 Sweden biobanks market, by application, 2018 - 2030 (USD Million)
Table 52 Norway biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 53 Norway biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 54 Norway biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 55 Norway biobanks market, by application, 2018 - 2030 (USD Million)
Table 56 Asia Pacific biobanks market, by region, 2018 - 2030 (USD Million)
Table 57 Asia Pacific biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 58 Asia Pacific biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 59 Asia Pacific biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 60 Asia Pacific biobanks market, by application, 2018 - 2030 (USD Million)
Table 61 China biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 62 China biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 63 China biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 64 China biobanks market, by application, 2018 - 2030 (USD Million)
Table 65 Japan biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 66 Japan biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 67 Japan biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 68 Japan biobanks market, by application, 2018 - 2030 (USD Million)
Table 69 India biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 70 India biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 71 India biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 72 India biobanks market, by application, 2018 - 2030 (USD Million)
Table 73 South Korea biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 74 South Korea biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 75 South Korea biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 76 South Korea biobanks market, by application, 2018 - 2030 (USD Million)
Table 77 Australia biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 78 Australia biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 79 Australia biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 80 Australia biobanks market, by application, 2018 - 2030 (USD Million)
Table 81 Thailand biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 82 Thailand biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 83 Thailand biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 84 Thailand biobanks market, by application, 2018 - 2030 (USD Million)
Table 85 Latin America biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 86 Latin America biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 87 Latin America biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 88 Latin America biobanks market, by application, 2018 - 2030 (USD Million)
Table 89 Brazil biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 90 Brazil biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 91 Brazil biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 92 Brazil biobanks market, by application, 2018 - 2030 (USD Million)
Table 93 Argentina biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 94 Argentina biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 95 Argentina biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 96 Argentina biobanks market, by application, 2018 - 2030 (USD Million)
Table 97 MEA biobanks market, by region, 2018 - 2030 (USD Million)
Table 98 MEA biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 99 MEA biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 100 MEA biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 101 MEA biobanks market, by application, 2018 - 2030 (USD Million)
Table 102 South Africa biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 103 South Africa biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 104 South Africa biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 105 South Africa biobanks market, by application, 2018 - 2030 (USD Million)
Table 106 Saudi Arabia biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia biobanks market, by application, 2018 - 2030 (USD Million)
Table 110 UAE biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 111 UAE biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 112 UAE biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 113 UAE biobanks market, by application, 2018 - 2030 (USD Million)
Table 114 Kuwait biobanks market, by product & services, 2018 - 2030 (USD Million)
Table 115 Kuwait biobanks market, by biospecimen type, 2018 - 2030 (USD Million)
Table 116 Kuwait biobanks market, by biobanks type, 2018 - 2030 (USD Million)
Table 117 Kuwait biobanks market, by application, 2018 - 2030 (USD Million)
List of Tables
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Biobanks market: market outlook
Fig. 9 Biobanks competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Biobanks market driver impact
Fig. 15 Biobanks market restraint impact
Fig. 16 Biobanks market strategic initiatives analysis
Fig. 17 Biobanks market: Product & services movement analysis
Fig. 18 Biobanks market: Product & services outlook and key takeaways
Fig. 19 Product market estimates and forecast, 2018 - 2030
Fig. 20 Biobanking equipment market estimates and forecast, 2018 - 2030
Fig. 21 Temperature control systems estimates and forecast, 2018 - 2030
Fig. 22 Freezers & refrigerators market estimates and forecast, 2018 - 2030
Fig. 23 Cryogenic storage systems market estimates and forecast, 2018 - 2030
Fig. 24 Thawing equipment market estimates and forecast, 2018 - 2030
Fig. 25 Incubators & centrifuges market estimates and forecast, 2018 - 2030
Fig. 26 Alarms & monitoring systems market estimates and forecast, 2018 - 2030
Fig. 27 Accessories & other equipment market estimates and forecast, 2018 - 2030
Fig. 28 Biobanking consumables market estimates and forecast, 2018 - 2030
Fig. 29 Laboratory information management systems market estimates and forecast, 2018 - 2030
Fig. 30 Services market estimates and forecasts, 2018 - 2030
Fig. 31 Biobanking & repository market estimates and forecasts, 2018 - 2030
Fig. 32 Lab processing market estimates and forecasts,2018 - 2030
Fig. 33 Qualification/ Validation market estimates and forecasts,2018 - 2030
Fig. 34 Cold chain logistics market estimates and forecasts, 2018 - 2030
Fig. 35 Other services market estimates and forecasts,2018 - 2030
Fig. 36 Biobanks market: Biospecimen type movement analysis
Fig. 37 Biobanks market: Biospecimen type outlook and key takeaways
Fig. 38 Human tissues market estimates and forecasts, 2018 - 2030
Fig. 39 Human organs market estimates and forecasts,2018 - 2030
Fig. 40 Stem cells market estimates and forecasts, 2018 - 2030
Fig. 41 Adult stem cells market estimates and forecasts,2018 - 2030
Fig. 42 Embryonic stem cells market estimates and forecasts, 2018 - 2030
Fig. 43 IPS cells market estimates and forecasts, 2018 - 2030
Fig. 44 Other stem cells market estimates and forecasts, 2018 - 2030
Fig. 45 Other biospecimens market estimates and forecasts, 2018 - 2030
Fig. 46 Biobanks market: Biobanks type movement analysis
Fig. 47 Biobanks market: Biobanks type outlook and key takeaways
Fig. 48 Physical/Real biobanks market estimates and forecasts, 2018 - 2030
Fig. 49 Tissue biobanks market estimates and forecasts,2018 - 2030
Fig. 50 Population based biobanks market estimates and forecasts, 2018 - 2030
Fig. 51 Genetic (DNA/RNA) market estimates and forecasts,2018 - 2030
Fig. 52 Disease based biobanks market estimates and forecasts, 2018 - 2030
Fig. 53 Virtual biobanks market estimates and forecasts, 2018 - 2030
Fig. 54 Biobanks market: Application movement analysis
Fig. 55 Biobanks market: Application outlook and key takeaways
Fig. 56 Therapeutics market estimates and forecasts, 2018 - 2030
Fig. 57 Drug discovery & clinical research market estimates and forecasts,2018 - 2030
Fig. 58 Clinical diagnostics market estimates and forecasts, 2018 - 2030
Fig. 59 Other applications market estimates and forecasts,2018 - 2030
Fig. 60 Global Biobanks market: Regional movement analysis
Fig. 61 Global Biobanks market: Regional outlook and key takeaways
Fig. 62 North America, by country
Fig. 63 North America
Fig. 64 North America market estimates and forecasts, 2018 - 2030
Fig. 65 U.S. country dynamics
Fig. 66 U.S. market estimates and forecasts, 2018 - 2030
Fig. 67 Canada country dynamics
Fig. 68 Canada market estimates and forecasts, 2018 - 2030
Fig. 69 Mexico country dynamics
Fig. 70 Mexico market estimates and forecasts, 2018 - 2030
Fig. 71 Europe market estimates and forecasts, 2018 - 2030
Fig. 72 UK country dynamics
Fig. 73 UK market estimates and forecasts, 2018 - 2030
Fig. 74 Germany country dynamics
Fig. 75 Germany market estimates and forecasts, 2018 - 2030
Fig. 76 France country dynamics
Fig. 77 France market estimates and forecasts, 2018 - 2030
Fig. 78 Italy country dynamics
Fig. 79 Italy market estimates and forecasts, 2018 - 2030
Fig. 80 Spain country dynamics
Fig. 81 Spain market estimates and forecasts, 2018 - 2030
Fig. 82 Denmark country dynamics
Fig. 83 Denmark market estimates and forecasts, 2018 - 2030
Fig. 84 Sweden country dynamics
Fig. 85 Sweden market estimates and forecasts, 2018 - 2030
Fig. 86 Norway country dynamics
Fig. 87 Norway market estimates and forecasts, 2018 - 2030
Fig. 88 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 89 China country dynamics
Fig. 90 China market estimates and forecasts, 2018 - 2030
Fig. 91 Japan country dynamics
Fig. 92 Japan market estimates and forecasts, 2018 - 2030
Fig. 93 India country dynamics
Fig. 94 India market estimates and forecasts, 2018 - 2030
Fig. 95 Thailand country dynamics
Fig. 96 Thailand market estimates and forecasts, 2018 - 2030
Fig. 97 South Korea country dynamics
Fig. 98 South Korea market estimates and forecasts, 2018 - 2030
Fig. 99 Australia country dynamics
Fig. 100 Australia market estimates and forecasts, 2018 - 2030
Fig. 101 Latin America market estimates and forecasts, 2018 - 2030
Fig. 102 Brazil country dynamics
Fig. 103 Brazil market estimates and forecasts, 2018 - 2030
Fig. 104 Argentina country dynamics
Fig. 105 Argentina market estimates and forecasts, 2018 - 2030
Fig. 106 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 107 South Africa country dynamics
Fig. 108 South Africa market estimates and forecasts, 2018 - 2030
Fig. 109 Saudi Arabia country dynamics
Fig. 110 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 111 UAE country dynamics
Fig. 112 UAE market estimates and forecasts, 2018 - 2030
Fig. 113 Kuwait country dynamics
Fig. 114 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 115 Market position of key market players- Biobanks market
Market Segmentation
Report content
Qualitative Analysis
Quantitative Analysis
Research Methodology
Grand View Research employs a comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecast possible. The company utilizes a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. In Addition, a recurring theme prevalent across all our research reports is data triangulation that looks market from three different perspectives. Critical elements of the methodology employed for all our studies include:
Preliminary data mining
Raw market data is obtained and collated on a broad front. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. For a comprehensive understanding of the market, it is essential to understand the complete value chain, and in order to facilitate this; we collect data from raw material suppliers, distributors as well as buyers.
Technical issues and trends are obtained from surveys, technical symposia, and trade journals. Technical data is also gathered from an intellectual property perspective, focusing on white space and freedom of movement. Industry dynamics with respect to drivers, restraints, pricing trends are also gathered. As a result, the material developed contains a wide range of original data that is then further cross-validated and authenticated with published sources.
Statistical model
Our market estimates and forecasts are derived through simulation models. A unique model is created customized for each study. Gathered information for market dynamics, technology landscape, application development, and pricing trends are fed into the model and analyzed simultaneously. These factors are studied on a comparative basis, and their impact over the forecast period is quantified with the help of correlation, regression, and time series analysis. Market forecasting is performed via a combination of economic tools, technological analysis, industry experience, and domain expertise.
Econometric models are generally used for short-term forecasting, while technological market models are used for long-term forecasting. These are based on an amalgamation of the technology landscape, regulatory frameworks, economic outlook, and business principles. A bottom-up approach to market estimation is preferred, with key regional markets analyzed as separate entities and integration of data to obtain global estimates. This is critical for a deep understanding of the industry as well as ensuring minimal errors. Some of the parameters considered for forecasting include:
• Market drivers and restraints, along with their current and expected impact
• Raw material scenario and supply v/s price trends
• Regulatory scenario and expected developments
• Current capacity and expected capacity additions up to 2030
We assign weights to these parameters and quantify their market impact using weighted average analysis, to derive an expected market growth rate.
Primary validation
This is the final step in estimating and forecasting for our reports. Exhaustive primary interviews are conducted, face to face as well as over the phone to validate our findings and assumptions used to obtain them. Interviewees are approached from leading companies across the value chain including suppliers, technology providers, domain experts, and buyers so as to ensure a holistic and unbiased picture of the market. These interviews are conducted across the globe, with language barriers overcome with the aid of local staff and interpreters. Primary interviews not only help in data validation but also provide critical insights into the market, current business scenario, and future expectations and enhance the quality of our reports. All our estimates and forecast are verified through exhaustive primary research with Key Industry Participants (KIPs) which typically include:
• Market-leading companies
• Raw material suppliers
• Product distributors
• Buyers
The key objectives of primary research are as follows:
• To validate our data in terms of accuracy and acceptability
• To gain an insight in to the current market and future expectations
Data Collection Matrix
Perspective |
Primary research |
Secondary research |
Supply-side |
|
|
Demand-side |
|
|
Industry Analysis Matrix
Qualitative analysis |
Quantitative analysis |
|
|
NEED A CUSTOM REPORT?
We offer custom report options, including stand-alone sections and country-level data. Special pricing is available for start-ups and universities.
Request CustomizationWe are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."